Compounded Semaglutide: Legality and Safety in 2026

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

• Most side effects of Ozempic (semaglutide) are short-term, resolving over time or with discontinuation of the medication.
• Long-term side effects may include pancreatitis, vision problems, kidney injury, and skin changes such as 'Ozempic face' or 'Ozempic body'.
• In one 2-year study, 8 people taking injectable Ozempic experienced pancreatitis, compared to 10 people taking a placebo.
• Wegovy® (semaglutide) is designed to be started low and increased slowly to help the body adjust and reduce side effects.

Semaglutide, available under brand names like Ozempic and Wegovy®, has become a widely discussed medication for managing type 2 diabetes and supporting weight loss. While its effectiveness is clear, understanding both its common and potential long-term side effects is critical for anyone considering or currently using these treatments. Most side effects are temporary, often improving as the body adjusts to the medication or after stopping it. However, some serious long-term issues can arise, including pancreatitis, vision problems, kidney injury, and noticeable skin changes often referred to as "Ozempic face." For instance, in one 2-year study, 8 people taking injectable Ozempic experienced pancreatitis, a serious inflammation of the pancreas, compared to 10 people taking a placebo. It is important to know that Wegovy® is designed to be started at a low dose and increased slowly. This approach helps the body adjust and can reduce the likelihood of severe side effects, especially nausea and other gastrointestinal symptoms. Our analysis aims to provide a clear picture of these potential outcomes based on available research.

What Are the Common Side Effects of Semaglutide?

Common side effects of semaglutide, found in medications like Ozempic, are typically mild to moderate. These issues often improve over time as your body gets used to the medication. When we examine the experiences of people starting Ozempic, we often see symptoms like abdominal pain, loss of appetite, indigestion, and reactions at the injection site.

Initial Adjustment Period

When someone first starts taking Ozempic or increases their dose, these symptoms are most likely to show up. The body needs time to adjust to the new medication. This adjustment period is normal, and for most people, the side effects improve within about three months. This means that the discomfort you might feel at the beginning is usually not a permanent state but a temporary phase as your system adapts. Understanding this can help manage expectations and reduce anxiety about these initial reactions.

Gastrointestinal Discomfort

Gastrointestinal issues are among the most frequently reported side effects. Users may experience nausea, vomiting, diarrhea, or abdominal pain. These symptoms can sometimes be severe. If not managed properly, they could even lead to dehydration or malnutrition. It is important to report any severe or persistent gastrointestinal discomfort to a healthcare provider. These issues are a common theme across many semaglutide users, highlighting the need for careful monitoring and management, especially during the initial stages of treatment.

Loss of Appetite and Indigestion

Many people report a loss of appetite while taking semaglutide. This effect contributes to weight loss, but it can also be uncomfortable. Indigestion or heartburn are also common complaints. These symptoms point to how semaglutide affects the digestive system, slowing down gastric emptying. While beneficial for blood sugar control and weight loss, this slower process can sometimes cause feelings of fullness, bloating, or discomfort after eating. Managing meal sizes and types of food can sometimes help ease these symptoms.

Injection Site Reactions

For injectable forms of semaglutide, like Ozempic, reactions at the injection site are possible. These can include redness, swelling, or itching where the medication was given. These reactions are usually mild and local. They typically resolve on their own. Proper injection technique and rotating injection sites can help minimize these occurrences. These reactions are not unique to semaglutide and are common with many injectable medications.

Hypoglycemia Concerns

Ozempic works by lowering blood sugar levels. This is a key benefit for people with diabetes. However, if blood sugar levels drop too low, it can lead to hypoglycemia. Symptoms of hypoglycemia include dizziness, confusion, fainting, or even seizures. Close monitoring of blood sugar is crucial, especially for individuals with diabetes. Hypoglycemia is particularly concerning for people without diabetes who use Ozempic solely for weight loss. These individuals might not be as accustomed to monitoring their blood sugar. They might not recognize the symptoms as quickly, which could lead to more severe outcomes. The product liability attorneys at Sullivan Papain Block McManus Coffinas & Cannavo P.C. stated, "Ozempic is a U.S. Food and Drug Administration-approved semaglutide medication primarily prescribed to individuals with Type 2 diabetes due to its ability to help regulate blood sugar levels. This effect can also contribute to weight loss." This underscores the drug's primary use and the importance of understanding its effects on blood sugar.

Managing Common Side Effects

Most of these common side effects are temporary. They often subside as the body adjusts to the medication. Healthcare providers can offer strategies to manage these symptoms, such as adjusting the dose, recommending dietary changes, or prescribing other medications to alleviate discomfort. It is essential for patients to communicate openly with their doctors about any side effects they experience. This ensures proper management and helps to maintain the effectiveness and safety of the treatment. Our goal is to ensure that patients are well-informed about what to expect during their treatment journey.

Can Semaglutide Cause Long-Term Health Problems?

Yes, semaglutide has been associated with certain long-term side effects that can persist for months or even years after stopping the medication. These issues extend beyond the initial adjustment period and require careful consideration. Our analysis reveals that these can include serious conditions such as pancreatitis, vision problems, kidney injury, and noticeable changes in skin appearance, sometimes referred to as 'Ozempic face' or 'Ozempic body'.

Extensive Clinical Trial Data

Clinical trials have provided substantial data on the long-term use of Ozempic. For type 2 diabetes, Ozempic was studied for 30 weeks. For cardiovascular outcomes, the SUSTAIN trials extended over 104 weeks. In adults with type 2 diabetes and chronic kidney disease, the medication was studied for 41 months. These lengthy study periods offer insights into potential long-term effects. The trials track side effects over extended periods, giving us a clearer picture of what can happen with prolonged use.

Pancreatitis: A Serious Concern

Pancreatitis, which is inflammation of the pancreas, is one of the rare but serious long-term side effects reported. While it is unclear if Ozempic directly causes pancreatitis, cases have been reported during clinical trials. This condition can lead to severe abdominal pain and digestive issues. It is potentially life-threatening. We urge patients to be aware of symptoms like severe upper stomach pain that might spread to the back, nausea, vomiting, or a rapid heartbeat. Pancreatitis usually resolves within two weeks, but there has been one report of chronic pancreatitis in a patient taking Ozempic during clinical trials. This highlights the potential for long-lasting complications.

Vision Problems and Eye Damage

Semaglutide may also worsen an existing eye condition called diabetic retinopathy. This can happen especially when blood sugar levels improve very quickly. In a 2-year study, 3% of Ozempic injection users experienced complications related to diabetic retinopathy, compared to 1.8% taking a placebo. For oral semaglutide, pooled trials showed 4.2% of users reported diabetic retinopathy, compared to 3.8% in the comparator group. Furthermore, Ozempic might cause a condition called non-arteritic anterior ischemic optic neuropathy (NAION). This occurs when the optic nerve does not receive enough blood supply, potentially leading to vision loss. These vision-related issues underscore the importance of regular eye exams for individuals on semaglutide, particularly those with a history of diabetes or existing eye conditions.

Kidney Damage and Function Loss

Kidney issues are another potential long-term complication. While Ozempic may help protect heart and kidney health in some people with type 2 diabetes or obesity, it can also lead to kidney injury or loss of kidney function in others. Monitoring kidney function is therefore an important part of ongoing care for patients using semaglutide. Any changes in kidney health should be promptly investigated by a healthcare provider. The balance between potential benefits and risks to kidney health needs careful consideration for each individual patient.

Changes in Body Composition: "Ozempic Face" and "Ozempic Body"

Rapid weight loss induced by semaglutide can lead to changes in body composition. These changes are often described as "Ozempic face" or "Ozempic body." This refers to a loss of volume in the face, which can make a person look older or gaunt, and similar changes in other body areas. While not a medical side effect in the traditional sense, these aesthetic changes can be a significant concern for some individuals. They are a direct consequence of significant and quick fat loss. This phenomenon is a visible marker of the drug's effectiveness in weight reduction, but it also points to the comprehensive impact on the body's fat stores.

Gallbladder Disease and Thyroid Tumors

Other rare but serious long-term side effects include gallbladder problems and a potential risk of thyroid tumors. Gallbladder disease and its complications are listed among the possible long-term issues. More concerning is the risk of thyroid tumors. In studies with rodents, Wegovy® and other medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not yet known if Wegovy® will cause thyroid tumors or a specific type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Patients are advised to tell their healthcare provider if they experience a lump or swelling in their neck, hoarseness, trouble swallowing, or shortness of breath. These could be symptoms of thyroid cancer. Individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use Wegovy®. This specific warning highlights a significant area of concern that requires careful screening and ongoing vigilance. Ozempic long-term side effects details many of these potential issues.

Mental Health Effects

Mental health effects are also noted as potential long-term Ozempic issues. While the specific nature and prevalence are not detailed in the provided research, this indicates a broader impact of the medication that extends beyond physical symptoms. It is important for healthcare providers and patients to monitor for any changes in mood or mental well-being while on semaglutide treatment. Any concerns should be discussed with a doctor to ensure comprehensive care.

Is Pancreatitis a Risk with Semaglutide?

Pancreatitis, an inflammation of the pancreas, has been reported in some individuals taking Ozempic, though it is considered a rare occurrence. The connection between semaglutide and pancreatitis is still being studied, and it remains unclear if the medication directly causes this condition. However, the potential for this serious side effect means patients need to be aware of the symptoms and risks.

Clinical Trial Findings on Pancreatitis

Clinical trials have provided some data on the incidence of pancreatitis. In one 2-year study, 8 people taking injectable Ozempic experienced pancreatitis. This was compared to 10 people taking a placebo, which had no active medication. This particular finding suggests that the rate of pancreatitis in the Ozempic group was not higher than in the placebo group in this specific study.

For oral semaglutide, which is found in products like Rybelsus, pooled studies reported 6 people experiencing pancreatitis. This was compared to 1 person in the comparator group. This difference might suggest a higher incidence with oral semaglutide in these pooled studies. However, interpreting these numbers requires careful context, as different studies can have varying designs and patient populations.

Meta-Analysis Results

A more recent and comprehensive meta-analysis looked at data from about 35,000 patients. This large-scale review found that semaglutide is not associated with a higher risk of pancreatitis when compared to a placebo. This meta-analysis provides a broader perspective, suggesting that across a large number of patients, the overall risk may not be significantly elevated. Despite this reassuring finding, individual cases of pancreatitis continue to be reported by people taking the medication. This means that while the statistical association might be low, the possibility still exists for individual patients.

Recognizing Symptoms of Pancreatitis

It is crucial for anyone taking semaglutide to be vigilant for the signs and symptoms of pancreatitis. These symptoms can be severe and require immediate medical attention. We advise patients to watch out for intense upper stomach pain that might spread to the back. Other key symptoms include nausea or vomiting, and a rapid heartbeat. These symptoms can indicate a serious inflammatory process in the pancreas. Pancreatitis typically resolves within two weeks. However, there has been one documented case of chronic (long-term) pancreatitis in a patient taking Ozempic during clinical trials. This shows that in rare instances, the condition can persist.

Importance of Patient Monitoring

Given the reports, even if rare, continuous monitoring of patients taking semaglutide for symptoms of pancreatitis is essential. Healthcare providers should educate patients about these risks. They should also instruct them on when to seek emergency care. The presence of these symptoms warrants an immediate medical evaluation to diagnose and treat pancreatitis promptly. Early detection and intervention can help prevent more severe complications. The decision to continue or discontinue semaglutide would depend on the severity of the pancreatitis and the overall clinical picture, always under the guidance of a healthcare professional. Potential complications of Ozempic also lists pancreatitis as a reported side effect, emphasizing its seriousness.

Pancreatitis and Weight Loss

While Ozempic is primarily known for its role in blood sugar regulation and weight loss, the potential link to pancreatitis adds another layer of consideration for its use. The mechanism by which semaglutide might contribute to pancreatitis is not fully understood. Some theories involve the drug's effects on pancreatic exocrine function or bile duct obstruction, though these are still areas of active research. The focus for patients should remain on symptom recognition and prompt reporting to their medical team. Even with large meta-analyses suggesting no higher risk, individual susceptibility and reactions can vary, making personalized medical advice indispensable.

How Does Semaglutide Affect Vision?

Semaglutide can have specific effects on vision, particularly for individuals with pre-existing conditions like diabetic retinopathy. Our review shows that the medication may worsen this eye condition, especially when blood sugar levels improve very rapidly. This rapid change can sometimes put stress on the delicate blood vessels in the eyes.

Impact on Diabetic Retinopathy

Diabetic retinopathy is a common complication of diabetes that affects the blood vessels in the retina. When blood sugar levels drop too quickly, it can paradoxically cause a temporary worsening of retinopathy. This phenomenon has been observed in clinical trials involving semaglutide. In a 2-year study, 3% of Ozempic injection users experienced complications related to diabetic retinopathy. This was compared to 1.8% of individuals taking a placebo. This difference highlights a potential increased risk for those on the active medication.

For oral semaglutide, such as Rybelsus, pooled placebo and active-controlled trials showed similar trends. In these trials, 4.2% of oral semaglutide users reported diabetic retinopathy. This was compared to 3.8% in the comparator group. While the difference appears smaller in the oral semaglutide group, it still indicates a slightly higher incidence compared to the control. These statistics suggest that monitoring eye health is a critical component of care for patients on semaglutide, especially those with diabetes.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Beyond diabetic retinopathy, Ozempic might also cause another serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). NAION occurs when the optic nerve, which transmits visual information from the eye to the brain, does not receive enough blood supply. This lack of blood flow can lead to sudden, painless vision loss in one eye. The exact link between semaglutide and NAION is not fully established. However, its mention as a potential side effect means that patients experiencing sudden vision changes should seek immediate medical attention. This condition can be permanent and significantly impact quality of life.

Importance of Regular Eye Examinations

Given these potential vision problems, we emphasize the importance of regular and thorough eye examinations for all patients using semaglutide, particularly those with diabetes. An ophthalmologist can monitor for any signs of diabetic retinopathy progression or other eye conditions. Early detection allows for timely intervention, which can help preserve vision. Patients should report any changes in their vision, no matter how subtle, to their healthcare provider without delay. This proactive approach is vital for managing the potential ocular risks associated with semaglutide.

Underlying Mechanisms and Risk Factors

The exact mechanisms by which semaglutide might affect vision are complex. For diabetic retinopathy, the rapid improvement in glycemic control is thought to be a trigger. The rapid shift can stress the retinal microvasculature, leading to temporary worsening. Over time, stable blood sugar control is beneficial for retinopathy, but the initial rapid phase needs careful management. For NAION, the link is less clear. However, conditions that affect blood flow, such as diabetes and hypertension, are known risk factors for NAION. While semaglutide helps manage diabetes, its direct contribution to NAION is an area that requires continued vigilance and research. Patients with existing vascular risk factors might be at higher risk for such complications.

Patient Education and Awareness

Educating patients about these potential vision changes is paramount. They should know that while semaglutide offers significant benefits for diabetes and weight management, it also carries specific risks that need attention. Clear communication from healthcare providers about symptoms to watch for, such as blurred vision, floaters, or sudden vision loss, can empower patients to seek help promptly. This comprehensive understanding of both benefits and risks ensures that patients make informed decisions about their treatment plan and maintain optimal health outcomes.

What are Other Serious Long-Term Risks of Semaglutide?

Beyond pancreatitis and vision issues, semaglutide can present other rare but serious long-term health risks. These include potential problems with the gallbladder, kidney issues, and a risk of thyroid tumors. Our review of the available data highlights that patients need to be aware of these serious complications, even if they are uncommon.

Gallbladder Disease and Complications

Gallbladder problems are listed among the potential long-term side effects of Ozempic. These can include gallstones (cholelithiasis) or inflammation of the gallbladder (cholecystitis). Rapid weight loss, which is a common effect of semaglutide, is a known risk factor for developing gallstones. These gallstones can cause severe abdominal pain, nausea, and vomiting. In some cases, they may require surgical intervention. While the exact incidence rate is not detailed in all sources, the mention of gallbladder disease as a serious long-term complication means it warrants attention. Patients experiencing symptoms such as sudden, intense pain in the upper right abdomen, often after eating fatty foods, should consult their doctor.

Kidney Damage and Function Loss

Semaglutide's impact on kidney health is complex. While it has been shown to protect heart and kidney health in some people with type 2 diabetes or obesity, it can also lead to kidney damage and loss of kidney function in other cases. This duality means that kidney function must be closely monitored throughout treatment. Dehydration, which can result from severe gastrointestinal side effects like vomiting and diarrhea, can also contribute to acute kidney injury. Therefore, managing common side effects effectively is crucial not just for comfort but also for protecting vital organs like the kidneys. Any changes in urine output, swelling in the legs or ankles, or unexplained fatigue should prompt a discussion with a healthcare provider.

Thyroid Tumors, Including Cancer

One of the most significant and concerning long-term risks identified is the potential for thyroid tumors, including cancer. This risk is clearly stated in the safety information for Wegovy®, another semaglutide product. In studies conducted with rodents, Wegovy® and other medications that work similarly caused thyroid tumors, including thyroid cancer. The critical caveat is that it is not yet known if Wegovy® will cause thyroid tumors or a specific type of thyroid cancer called medullary thyroid carcinoma (MTC) in humans.

However, the warning is serious enough to advise patients to be vigilant. They should tell their healthcare provider immediately if they notice a lump or swelling in their neck, experience hoarseness, have trouble swallowing, or feel short of breath. These symptoms could indicate thyroid cancer. Furthermore, Wegovy® should not be used if an individual or any family member has ever had medullary thyroid carcinoma (MTC) or if they have an endocrine system condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). These are strong contraindications that emphasize the potential severity of this risk.

Gastrointestinal Complications: Stomach Paralysis and Intestinal Blockage

Beyond the common gastrointestinal discomforts, semaglutide can, in rare instances, lead to more severe gastrointestinal complications. These include gastroparesis, commonly known as stomach paralysis, and intestinal blockage. Gastroparesis means the stomach empties food into the small intestine much slower than normal. This can cause severe nausea, vomiting, bloating, and early fullness. An intestinal blockage, on the other hand, is a serious condition where there is a partial or complete blockage of the small or large intestine. Both conditions are rare but can be debilitating and require urgent medical attention. Symptoms like persistent vomiting, severe abdominal pain, inability to pass gas or stool, and abdominal distension should be reported to a doctor immediately.

Body Composition Changes: "Ozempic Face" and "Ozempic Body"

While not a direct medical pathology, the rapid weight loss facilitated by semaglutide can lead to significant changes in body composition. These are often colloquially termed "Ozempic face" or "Ozempic body." This refers to the loss of fat volume in certain areas, particularly the face, which can result in a gaunt or aged appearance. Similar effects can be observed in other parts of the body, where rapid fat loss changes the overall contour. These effects are a consequence of the drug's efficacy in reducing body fat. While many seek weight loss, the aesthetic implications of such rapid changes can be a concern for some individuals. These changes highlight the profound impact semaglutide can have on the body's fat stores.

Mental Health Effects

Mental health effects are also among the long-term Ozempic issues mentioned. While specific details are scarce in the provided research, this indicates a need for awareness regarding potential psychological impacts. Patients and providers should monitor for any changes in mood, anxiety, or other mental health symptoms during treatment. Open communication about emotional well-being is as important as discussing physical symptoms.

Overall Risk Assessment

In our assessment, it is clear that while semaglutide offers significant health benefits for many, particularly in managing type 2 diabetes and promoting weight loss, it is not without serious long-term risks. Patients and healthcare providers must engage in a thorough discussion about these potential complications. This includes a careful review of personal and family medical history before starting treatment. Ongoing vigilance and prompt reporting of any new or worsening symptoms are essential for safe and effective use of the medication.

How is Wegovy® Dosed for Weight Loss?

Wegovy® (semaglutide) is specifically designed for weight loss, and its dosing schedule is carefully structured. The medication is always started at a low dose and then increased slowly over time. This gradual increase is a critical strategy to help the body adjust to the medication, which in turn can significantly reduce the likelihood of side effects, especially common issues like nausea and other gastrointestinal symptoms that might otherwise disrupt treatment.

The Gradual Titration Schedule

The dosing schedule for Wegovy® typically ranges from an initial dose of 0.25mg and gradually increases up to a maximum of 2.4mg. This step-by-step approach is known as titration. It is implemented to minimize the patient's discomfort and allow their system to slowly adapt to the drug's effects. The process usually involves weekly injections, with dose increases occurring every four weeks or so, depending on individual tolerance and medical guidance. This careful escalation ensures that the body has ample time to adjust to the medication, making the treatment more tolerable and sustainable in the long run.

Why Gradual Dosing is Important

The primary reason for this gradual titration is to mitigate side effects. Semaglutide works by mimicking a hormone that affects appetite and digestion, including slowing down gastric emptying. When the body is introduced to these effects too quickly, it can lead to significant gastrointestinal distress. By starting with a low dose, the body can slowly get used to these changes, which helps to reduce the severity and frequency of symptoms such as nausea, vomiting, diarrhea, and constipation. This approach is key to keeping patients on track with their treatment. As stated by bodyspec.com in an update from December 2025, "Wegovy® (semaglutide) is designed to be started low and increased slowly. Gradual titration helps your body adjust, which can reduce the likelihood that side effects (especially nausea and other GI symptoms) disrupt treatment." This expert consensus reinforces the importance of the dosing strategy.

Typical Dosing Increments

A typical Wegovy® dosing guide, as of 2026, outlines a schedule that involves several steps. For example, a patient might start at 0.25mg once weekly for the first four weeks. Then, the dose might increase to 0.5mg for another four weeks, followed by 1.0mg, 1.7mg, and finally 2.4mg, with each increase also lasting approximately four weeks. This structured progression ensures that patients reach the effective therapeutic dose while managing side effects. Each dose increase is a decision made in consultation with a healthcare provider, who assesses the patient's tolerance and response to the current dose.

Managing Side Effects During Dosing Increases

Even with gradual titration, some patients may still experience side effects during dose increases. These are usually temporary and diminish as the body adjusts to the new level of medication. Healthcare providers offer guidance on managing these symptoms, which might include dietary adjustments, timing of the injection, or other supportive measures. It is important for patients to communicate any discomfort or persistent side effects to their doctor. This allows for potential adjustments to the dosing schedule, such as delaying an increase or even returning to a lower dose if necessary, to ensure patient comfort and adherence to the treatment.

Wegovy® Pen and Pill Formulations

Wegovy® is available in both an injectable pen and, potentially, an oral pill form. The dosing principles remain the same: start low and go slow. The Wegovy® pen guide provides detailed instructions for administration, ensuring patients can safely and correctly inject the medication themselves. Similarly, information for the Wegovy® pill also emphasizes the importance of following the prescribed dosing schedule. Whether using the pen or the pill, adherence to the gradual titration schedule is fundamental for both efficacy and safety. Wegovy dosing guide 2026 offers comprehensive details on this schedule.

Long-Term Adherence and Efficacy

The careful dosing strategy for Wegovy® is also crucial for long-term adherence and achieving sustained weight loss. If side effects are too severe early on, patients might discontinue the medication, missing out on its potential benefits. By making the initial phase of treatment as tolerable as possible, the gradual titration helps patients stay on the medication long enough to reach the maintenance dose where they can experience the most significant weight loss results. This strategic approach underlines the commitment to patient safety and treatment effectiveness in the use of semaglutide for weight management.

Frequently Asked Questions

What are the most common side effects when starting Ozempic?

When first starting Ozempic or increasing the dose, the most common side effects are mild to moderate gastrointestinal issues. These include abdominal pain or discomfort, loss of appetite, indigestion or heartburn, and reactions at the injection site like redness or swelling. These symptoms are generally temporary and tend to improve as your body adjusts to the medication, often subsiding within about 3 months. In one 2-year study, these initial symptoms were frequently reported, but their severity usually decreased over time.

Can Ozempic cause stomach paralysis?

Yes, Ozempic can cause gastrointestinal complications like gastroparesis, also known as stomach paralysis. This condition means the stomach empties food much slower than normal. While considered rare, it is a serious long-term side effect. Symptoms can include severe nausea, vomiting, bloating, and feeling full very quickly after eating. It is important to report such persistent and severe gastrointestinal issues to your healthcare provider immediately.

Is there a risk of thyroid cancer with semaglutide?

In studies with rodents, Wegovy® and other medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or medullary thyroid carcinoma (MTC) in people. However, patients should tell their healthcare provider if they get a lump or swelling in their neck, hoarseness, trouble swallowing, or shortness of breath, as these may be symptoms of thyroid cancer. Do not use Wegovy® if you or your family have had MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

How long do Ozempic side effects typically last?

Most side effects of Ozempic are short-term and resolve over time or when you stop taking the medication. For many people, common side effects like nausea and abdominal discomfort improve within about 3 months as their body adjusts to the medication. However, some long-term problems, such as pancreatitis, vision problems, kidney injury, and skin changes, may last months or years after stopping the drug, even though these are rare.

What should I watch for if I suspect pancreatitis from Ozempic?

If you suspect pancreatitis from Ozempic, you should watch out for severe upper stomach pain that may radiate to the back. Other key symptoms include nausea or vomiting and a rapid heartbeat. Pancreatitis is an inflammation of the pancreas and can be a serious, potentially life-threatening condition. In one 2-year study, 8 people taking injectable Ozempic experienced pancreatitis, and immediate medical attention is necessary if these symptoms appear.

Sources

1. https://www.drugs.com/medical-answers/what-long-term-side-effects-ozempic-3578238/
2. https://www.triallaw1.com/potential-complications-and-long-term-effects-of-ozempic/
3. https://ro.co/weight-loss/long-term-side-effects-of-ozempic/
4. https://www.wegovy.com/obesity/starting-wegovy/starting-wegovy-pen.html
5. https://pandameds.com/blog/wegovy-dosing-guide/
6. https://www.bodyspec.com/blog/post/wegovy_dosing_chart_and_weekly_schedule

---

Related Reading

• Wegovy Long-Term Weight Loss: SELECT Trial Results
• Compounded Semaglutide: Is It Safe? [2026 Update]
• Wegovy Linked to 5x Higher Vision Loss Risk (Study)
• Best GLP-1 Medications for Weight Loss [2026]
• Compounded vs Brand Name GLP-1: Safety, Cost, and Legality [2026]

— The The GLP-1 Daily Team